Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.

Sollano JA, Kirsch JM, Bala MV, Chambers MG, Harpole LH.

Clin Pharmacol Ther. 2008 Aug;84(2):263-6. doi: 10.1038/clpt.2008.117. Epub 2008 Jun 11.

PMID:
18547999
3.

Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.

Bala MV, Zarkin GA, Mauskopf J.

Health Econ. 2008 Mar;17(3):435-40.

PMID:
17694580
4.

Overview of the pharmacoeconomics of pharmacogenetics.

Dervieux T, Bala MV.

Pharmacogenomics. 2006 Dec;7(8):1175-84. Review.

PMID:
17184205
5.

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV.

J Rheumatol. 2006 Nov;33(11):2167-72. Epub 2006 Sep 1.

PMID:
16981296
6.
7.

On pharmacogenomics and cost-effectiveness analysis at the individual level.

Bala MV, Zarkin GA.

Pharmacoeconomics. 2005;23(5):527. No abstract available.

PMID:
15896103
8.

Health economic analysis of new interventions: are we asking the right questions?

Bala MV.

Expert Rev Pharmacoecon Outcomes Res. 2004 Aug;4(4):365-6. doi: 10.1586/14737167.4.4.365. No abstract available.

PMID:
19807294
9.
10.

Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.

Bala MV, Zarkin GA, Mauskopf JA.

Value Health. 2002 Jul-Aug;5(4):338-46. Review.

11.
12.

Estimating the Bayesian loss function. A conjoint analysis approach.

Bala MV, Mauskopf J.

Int J Technol Assess Health Care. 2001 Winter;17(1):27-37.

PMID:
11329843
13.

Annual cost of care for Crohn's disease: a payor perspective.

Feagan BG, Vreeland MG, Larson LR, Bala MV.

Am J Gastroenterol. 2000 Aug;95(8):1955-60.

PMID:
10950042
14.

Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.

Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA.

Pharmacoeconomics. 2000 Apr;17(4):351-60. Review.

PMID:
10947490
15.

Are QALYs an appropriate measure for valuing morbidity in acute diseases?

Bala MV, Zarkin GA.

Health Econ. 2000 Mar;9(2):177-80.

PMID:
10721019
16.

Estimating the willingness to pay for drug abuse treatment: a pilot study.

Zarkin GA, Cates SC, Bala MV.

J Subst Abuse Treat. 2000 Mar;18(2):149-59.

PMID:
10716098
17.

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique.

Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH.

Chest. 2000 Feb;117(2):542-50. Review.

PMID:
10669701
19.

Are health states "timeless"? The case of the standard gamble method.

Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien BJ.

J Clin Epidemiol. 1999 Nov;52(11):1047-53.

PMID:
10526998
20.

Willingness to pay as a measure of health benefits.

Bala MV, Mauskopf JA, Wood LL.

Pharmacoeconomics. 1999 Jan;15(1):9-18. Review.

PMID:
10345161
21.

Cost effectiveness of pramipexole in Parkinson's disease in the US.

Hoerger TJ, Bala MV, Rowland C, Greer M, Chrischilles EA, Holloway RG.

Pharmacoeconomics. 1998 Nov;14(5):541-57.

PMID:
10344917
22.

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.

Anderson KM, Bala MV, Weisman HF.

Am Heart J. 1999 May;137(5):S129-32. No abstract available.

PMID:
10220615
23.

Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years.

Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B.

J Clin Epidemiol. 1998 Aug;51(8):667-76.

PMID:
9743315
24.

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults.

Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J.

Am J Cardiol. 1998 Jul 1;82(1):61-5.

PMID:
9671010
25.
26.

Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.

Zarkin GA, Bala MV, Wood LL, Bennett CL, Simpson K, Dohn MN.

Pharmacoeconomics. 1996 Jun;9(6):525-34.

PMID:
10160480

Supplemental Content

Support Center